Stock listing
gettex:48Q0 X4 Pharmaceuticals, Inc. Aktie
German listing (gettex) of X4 Pharmaceuticals, Inc. · home listing NASDAQ:XFOR
Follow X4 Pharmaceuticals, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:XFOR
$3.00 USD +0.02 (+0.7%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:XFOR
- Day range
- $2.89 – $3.06 USDNov 20, 2026
- Volume
- 1.83M sharesNov 20, 2026
- Market cap
- $306.3M USDAt the close on Nov 20, 2026 · price × 102.1M shares outstanding
- 52-week range
- $2.43 – $4.83 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $2.85M USDMedian day 642,500 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:XFOR · Home | $3.00 USD | +0.02 (+0.7%) | 1,825,293 | $2.93 | $3.06 | $2.89 | $2.98 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:XFOR · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $3.00 | +0.02 | +0.7% | $2.93 | $3.06 | $2.89 | 1,825,293 | |
| $2.98 | -0.11 | -3.6% | $3.09 | $3.268 | $2.965 | 642,205 | |
| $3.09 | +0.26 | +9.2% | $2.87 | $3.11 | $2.81 | 1,113,447 | |
| $2.83 | -0.29 | -9.3% | $3.10 | $3.13 | $2.82 | 672,340 | |
| $3.12 | -0.05 | -1.6% | $3.20 | $3.20 | $2.975 | 501,341 | |
| $3.17 | -0.06 | -1.9% | $3.18 | $3.20 | $2.95 | 2,163,082 | |
| $3.23 | -0.015 | -0.5% | $3.27 | $3.36 | $3.175 | 775,738 | |
| $3.245 | -0.085 | -2.6% | $3.29 | $3.35 | $3.22 | 467,510 | |
| $3.33 | +0.15 | +4.7% | $3.24 | $3.45 | $3.18 | 891,254 | |
| $3.18 | +0.11 | +3.6% | $3.04 | $3.205 | $2.90 | 527,189 | |
| $3.07 | -0.17 | -5.2% | $3.07 | $3.13 | $2.895 | 607,556 | |
| $3.24 | +0.07 | +2.2% | $3.30 | $3.36 | $3.11 | 536,564 | |
| $3.17 | -0.18 | -5.4% | $3.37 | $3.42 | $3.135 | 630,983 | |
| $3.35 | 0.00 | 0.0% | $3.40 | $3.47 | $3.26 | 521,958 | |
| $3.35 | -0.01 | -0.3% | $3.33 | $3.41 | $3.19 | 706,226 | |
| $3.36 | +0.01 | +0.3% | $3.39 | $3.49 | $3.05 | 908,046 | |
| $3.35 | +0.10 | +3.1% | $3.24 | $3.36 | $3.14 | 534,947 | |
| $3.25 | 0.00 | 0.0% | $3.20 | $3.30 | $3.05 | 1,607,224 | |
| $3.25 | +0.01 | +0.3% | $3.265 | $3.30 | $3.14 | 701,646 | |
| $3.24 | +0.04 | +1.3% | $3.16 | $3.25 | $3.02 | 536,600 | |
| $3.20 | +0.19 | +6.3% | $2.99 | $3.28 | $2.96 | 591,800 | |
| $3.01 | -0.01 | -0.3% | $3.02 | $3.12 | $2.875 | 406,900 | |
| $3.02 | +0.27 | +9.8% | $2.79 | $3.07 | $2.77 | 593,300 | |
| $2.75 | +0.16 | +6.2% | $2.60 | $2.82 | $2.58 | 603,000 | |
| $2.59 | -0.05 | -1.9% | $2.64 | $2.71 | $2.52 | 967,600 | |
| $2.64 | +0.19 | +7.8% | $2.48 | $2.655 | $2.475 | 549,800 | |
| $2.45 | -0.15 | -5.8% | $2.54 | $2.55 | $2.43 | 705,700 | |
| $2.60 | -0.22 | -7.8% | $2.81 | $2.83 | $2.59 | 439,500 | |
| $2.82 | -0.09 | -3.1% | $2.89 | $2.93 | $2.81 | 404,300 | |
| $2.91 | +0.12 | +4.3% | $2.83 | $2.965 | $2.815 | 541,200 | |
| $2.79 | -0.02 | -0.7% | $2.77 | $2.81 | $2.70 | 836,500 | |
| $2.81 | +0.04 | +1.4% | $2.74 | $2.86 | $2.70 | 435,400 | |
| $2.77 | -0.13 | -4.5% | $2.90 | $2.90 | $2.70 | 642,500 | |
| $2.90 | +0.07 | +2.5% | $2.88 | $2.935 | $2.73 | 698,100 | |
| $2.83 | 0.00 | 0.0% | $2.86 | $2.86 | $2.745 | 911,400 | |
| $2.83 | -0.07 | -2.4% | $2.89 | $2.95 | $2.82 | 501,500 | |
| $2.90 | 0.00 | 0.0% | $2.93 | $2.935 | $2.845 | 1,764,600 | |
| $2.90 | -0.115 | -3.8% | $3.01 | $3.055 | $2.895 | 1,709,300 | |
| $3.015 | +0.005 | +0.2% | $2.996 | $3.04 | $2.81 | 838,300 | |
| $3.01 | +0.01 | +0.3% | $2.98 | $3.083 | $2.965 | 1,856,500 | |
| $3.00 | -0.11 | -3.5% | $3.10 | $3.10 | $2.955 | 973,600 | |
| $3.11 | -0.32 | -9.3% | $3.41 | $3.42 | $3.035 | 2,309,100 | |
| $3.43 | -0.065 | -1.9% | $3.52 | $3.57 | $3.40 | 922,400 | |
| $3.495 | -0.085 | -2.4% | $3.58 | $3.58 | $3.455 | 444,400 | |
| $3.58 | +0.08 | +2.3% | $3.48 | $3.635 | $3.48 | 1,543,400 | |
| $3.50 | -0.01 | -0.3% | $3.56 | $3.585 | $3.41 | 635,100 | |
| $3.51 | -0.11 | -3.0% | $3.63 | $3.65 | $3.355 | 973,300 | |
| $3.62 | 0.00 | 0.0% | $3.60 | $3.64 | $3.31 | 2,081,100 | |
| $3.62 | +0.12 | +3.4% | $3.51 | $3.711 | $3.47 | 1,017,900 | |
| $3.50 | +0.10 | +2.9% | $3.44 | $3.55 | $3.24 | 1,252,900 | |
| $3.40 | -0.20 | -5.6% | $3.60 | $3.675 | $3.31 | 2,570,100 | |
| $3.60 | +0.095 | +2.7% | $3.50 | $3.67 | $3.45 | 1,402,200 | |
| $3.505 | -0.535 | -13.2% | $4.00 | $4.125 | $3.19 | 2,322,400 | |
| $4.04 | 0.00 | 0.0% | $4.01 | $4.08 | $4.00 | 168,200 | |
| $4.04 | 0.00 | 0.0% | $4.06 | $4.069 | $3.99 | 409,400 | |
| $4.04 | -0.03 | -0.7% | $4.10 | $4.17 | $4.015 | 361,000 | |
| $4.07 | +0.03 | +0.7% | $3.97 | $4.11 | $3.97 | 203,800 | |
| $4.04 | 0.00 | 0.0% | $4.02 | $4.10 | $4.00 | 245,900 | |
| $4.04 | -0.19 | -4.5% | $4.22 | $4.23 | $4.00 | 356,200 | |
| $4.23 | +0.06 | +1.4% | $4.18 | $4.39 | $4.145 | 597,200 | |
| $4.17 | +0.01 | +0.2% | $4.16 | $4.23 | $4.075 | 707,100 | |
| $4.16 | +0.11 | +2.7% | $4.05 | $4.18 | $3.995 | 390,755 | |
| $4.05 | +0.01 | +0.2% | $4.03 | $4.095 | $3.94 | 299,166 | |
| $4.04 | +0.01 | +0.2% | $4.05 | $4.175 | $4.005 | 1,219,600 | |
| $4.03 | -0.13 | -3.1% | $4.12 | $4.22 | $3.99 | 561,200 |
Splits
2 splits since 2019 · NASDAQ:XFOR · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-30 | Consolidation | |
| 1-for-6 | Consolidation |
- Ticker
- gettex:48Q0
- Asset type
- Stock
- Exchange
- gettex
- Currency
- EUR
What changed lately
Latest news release · Nov 4, 2026
X4 Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Latest deck · Oct 29, 2026
Investor Day (October 2026)
Investor day · 34 slides
Latest news
X4 Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Nov 4, 2026
Closed $3.07 (-5.2%) on Nov 5, 2026
X4 Pharmaceuticals to Participate in Guggenheim, Stifel, and Jefferies Conferences in November 2026
Nov 3, 2026
Closed $3.24 (+2.2%) on Nov 4, 2026
X4 Pharmaceuticals Highlights Clinical Progress and Market Opportunity for Mavorixafor in Primary Chronic Neutropenia During Virtual Investor Day
Oct 29, 2026
Closed $3.35 (-0.3%) on Oct 30, 2026
X4 Pharmaceuticals to Host Virtual Investor Day on Thursday, October 29, 2026, Featuring Key Opinion Leaders
Oct 9, 2026
Closed $2.91 (+4.3%) on Oct 9, 2026
X4 Pharmaceuticals Secures Up to $150 Million Senior Debt Facility with K2 HealthVentures
Oct 8, 2026
Closed $2.79 (-0.7%) on Oct 8, 2026
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 1, 2026
Closed $2.83 (0.0%) on Oct 2, 2026
X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference
Sep 9, 2026
Closed $3.60 (+2.7%) on Sep 9, 2026
X4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting
Sep 8, 2026
Closed $3.51 (-13.2%) on Sep 8, 2026
X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Aug 6, 2026
Closed $4.64 (+11.3%) on Aug 7, 2026
X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors
Jul 1, 2026
Closed $4.09 (-12.5%) on Jul 1, 2026
X4 Pharmaceuticals, Inc. on 6ix
- News releases
- 22 in the last 12 months · 130 in all · newest Nov 4, 2026 · oldest 2019
- Calls
- 19 calls with a replay · 19 with a transcript · latest May 1, 2025
- Decks
- 23 decks · latest Oct 29, 2026
Where X4 Pharmaceuticals, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:XFOR · Home listing | NASDAQ | United States | USD |
| BOATS:XFOR | BOATS | United States | USD |
| gettex:48Q0 · This page | gettex | Germany | EUR |
| Lang & Schwarz:A3E4QR | Lang & Schwarz | Germany | EUR |
| Frankfurt:48Q0 | Frankfurt | Germany | EUR |
| LS Exchange:A3E4QR | LS Exchange | Germany | EUR |
Valuation
Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $193.6M USD
- P/E
- Loss
- EV/sales
- 19.4×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 2.2×
- Gross margin
- 138.5%
- Operating margin
- −803.9%
- Net margin
- −805.2%
- Debt to equity
- 0.5×
- Beta vs S&P 500
- 1.35
Forecasts
5 strong buy · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.
- Price target
- 11.60 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.64 · 5 analysts
- Revenue, year to Dec 2026
- 17.28M · 5 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Paula Ragan | CEO & President |
| David Kirske | Chief Financial Officer |
| John Volpone | President, Chief Operating Officer |
| Adam Craig | Executive Chair |
Board
| Director | Role |
|---|---|
| Adam Craig | Executive Chair |
| Françoise de Craecker | Board Member |
| Gary L. Bridger | Board Member |
| Michael Wyzga | Lead Independent Director |
| Murray Stewart | Board Member |
Events
Calls
| Call | When | Status |
|---|---|---|
| X4 Pharmaceuticals (NASDAQ:XFOR) Q1 2025 Earnings Call | Wed, Apr 30, 2025 · 10:30 PM ET | Replay |
| X4 Pharmaceuticals (NASDAQ:XFOR) Q4 2024 Earnings Call | Tue, Mar 25, 2025 · 8:30 AM ET | Replay |
| X4 Pharmaceuticals (NASDAQ:XFOR) Q3 2024 Earnings Call | Wed, Nov 13, 2024 · 8:00 AM ET | Replay |
| X4 Pharmaceuticals (NASDAQ:XFOR) Q2 2024 Earnings Call | Thu, Aug 08, 2024 · 8:30 AM ET | Replay |
| X4 Pharmaceuticals (NASDAQ:XFOR) Q1 2024 Earnings Call | Tue, May 07, 2024 · 8:30 AM ET | Replay |
| X4 Pharmaceuticals (NASDAQ:XFOR) Q4 2023 Earnings Call | Thu, Mar 21, 2024 · 8:30 AM ET | Replay |
| X4 Pharmaceuticals (NASDAQ:XFOR) Q3 2023 Earnings Call | Thu, Nov 09, 2023 · 8:30 AM ET | Replay |
| X4 Pharmaceuticals (NASDAQ:XFOR) Q2 2023 Earnings Call | Thu, Aug 10, 2023 · 8:30 AM ET | Replay |
| X4 Pharmaceuticals (NASDAQ:XFOR) Q1 2023 Earnings Call | Thu, May 04, 2023 · 8:30 AM ET | Replay |
| X4 Pharmaceuticals (NASDAQ:XFOR) Q4 2022 Earnings Call | Tue, Mar 21, 2023 · 9:00 AM ET | Replay |
All 19 calls
| Call | When | Status |
|---|---|---|
| X4 Pharmaceuticals (NASDAQ:XFOR) Q3 2022 Earnings Call | Thu, Nov 03, 2022 · 8:30 AM ET | Replay |
| X4 Pharmaceuticals (NASDAQ:XFOR) Q2 2022 Earnings Call | Thu, Aug 04, 2022 · 8:30 AM ET | Replay |
| X4 Pharmaceuticals (NASDAQ:XFOR) Q1 2022 Earnings Call | Thu, May 12, 2022 · 8:30 AM ET | Replay |
| X4 Pharmaceuticals (NASDAQ:XFOR) Q4 2021 Earnings Call | Thu, Mar 17, 2022 · 8:30 AM ET | Replay |
| X4 Pharmaceuticals (NASDAQ:XFOR) Q3 2021 Earnings Call | Thu, Nov 04, 2021 · 9:00 AM ET | Replay |
| X4 Pharmaceuticals (NASDAQ:XFOR) Q2 2021 Earnings Call | Tue, Aug 03, 2021 · 8:30 AM ET | Replay |
| X4 Pharmaceuticals (NASDAQ:XFOR) Q1 2021 Earnings Call | Thu, May 06, 2021 · 8:30 AM ET | Replay |
| X4 Pharmaceuticals (NASDAQ:XFOR) Q4 2020 Earnings Call | Thu, Mar 04, 2021 · 8:30 AM ET | Replay |
| X4 Pharmaceuticals (NASDAQ:XFOR) Q3 2020 Earnings Call | Thu, Oct 22, 2020 · 9:30 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 4, 2026 · After close | −5.3% |
| Q2 2026 | Aug 6, 2026 · After close | +11.3% |
| Q1 2026 | May 6, 2026 · Before open | +4.3% |
| Q4 2025 | Mar 17, 2026 | +13.8% |
| Q3 2025 | Nov 5, 2025 · Before open | −10.6% |
| Q2 2025 | Aug 8, 2025 · After close | −4.7% |
| Q1 2025 | May 1, 2025 · Before open | −13.0% |
| Q4 2024 | Mar 19, 2025 · Before open | +1.7% |
| Q3 2024 | Nov 13, 2024 · Before open | −53.2% |
| Q2 2024 | Aug 8, 2024 · Before open | +3.3% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 7, 2024 · Before open | −9.2% |
| Q4 2023 | Mar 21, 2024 · Before open | +28.4% |
| Q3 2023 | Nov 9, 2023 · Before open | +6.6% |
| Q2 2023 | Aug 10, 2023 · Before open | −36.0% |
| Q1 2023 | May 4, 2023 · Before open | +4.0% |
| Q4 2022 | Mar 21, 2023 · Before open | +0.9% |
| Q3 2022 | Nov 3, 2022 · Before open | −3.6% |
| Q2 2022 | Aug 4, 2022 · Before open | −1.6% |
| Q1 2022 | May 12, 2022 · Before open | −0.9% |
| Q4 2021 | Mar 17, 2022 · Before open | −10.6% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Day (October 2026) | Investor day | 34 slides | Oct 29, 2026 |
| Investor Presentation (October 2026) | Investor deck | 20 slides | October 2026 |
| Investor Presentation (September 2026) | Investor deck | 20 slides | Sep 9, 2026 |
| Investor Presentation (May 2025) | Investor deck | 32 slides | May 1, 2025 |
| Investor Presentation (January 2025) | Investor deck | 32 slides | Jan 13, 2025 |
| Q3 2024 Earnings Presentation | Earnings | 28 slides | Nov 13, 2024 |
| Investor Day (June 2024) | Investor day | 31 slides | Jun 27, 2024 |
| Investor Presentation (May 2024) | Investor deck | 26 slides | May 22, 2024 |
| Corporate Update (April 2024) | Corporate update | 26 slides | Apr 29, 2024 |
| Technical Presentation (February 2024) | Technical | 15 slides | February 2024 |
All 23 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Day (May 2023) | Investor day | 29 slides | May 16, 2023 |
| Technical Presentation (May 2023) | Technical | 23 slides | May 2023 |
| Technical Presentation (May 2023) | Technical | 20 slides | May 2023 |
| ASH 2022 | Conference | 16 slides | December 2022 |
| Corporate Update (November 2022) | Corporate update | 19 slides | Nov 29, 2022 |
| Q3 2022 Earnings Presentation | Earnings | 18 slides | Nov 3, 2022 |
| Technical Presentation (November 2022) | Technical | 11 slides | November 2022 |
| Technical Presentation (September 2022) | Technical | 24 slides | Sep 27, 2022 |
| Investor Presentation (August 2022) | Investor deck | 25 slides | Aug 5, 2022 |
| ASH 2021 | Conference | 8 slides | Dec 16, 2021 |
| Technical Presentation (September 2019) | Technical | 15 slides | Sep 30, 2019 |
| Investor Presentation (April 2019) | Investor deck | 20 slides | Apr 1, 2019 |
| Arsanis — Merger or Acquisition (November 2018) | Merger or acquisition | 20 slides | Nov 27, 2018 |
Financings
| Raise | Date |
|---|---|
| Public offering of shares of common stock and pre-funded warrants Closed: US$155.3M raised · US$2.9 a share · Leerink Partners +2 Dealers: Leerink Partners (co-lead), Stifel (co-lead), Guggenheim Securities (co-lead) Use of proceeds: Fund pivotal Phase 3 development of mavorixafor in chronic neutropenic disorders, G&A, capital expenditures, working capital and general corporate purposes | Oct 27, 2025 |
| Private placement of shares of common stock and pre-funded warrants Closed: US$85M raised · US$1.42 a share · Stifel Dealers: Stifel (lead) Buyers: Coastlands Capital (led the offering); Bain Capital Life Sciences (existing investor); New Enterprise Associates; BVF Partners LP; Deep Track Capital; Kalehua Capital; Nantahala Capital; Stonepine Capital Management; Trails Edge Capital Partners; Empery Asset Management, LP (existing investor); New Enterprise Associates (NEA) (existing investor) Use of proceeds: Continued development towards potential additional approval of mavorixafor in chronic neutropenia and commercialization in WHIM | Aug 13, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Went public as Arsanis, Inc. Priced at US$10.00 a share on Nov 15, 2017.
- Price
- US$10.00 a share
- Shares offered
- 4,000,000 shares of common stock
- Offering size
- US$40 million
- Underwriters' option
- Up to 600,000 more shares
- Underwriters
- Citigroup, Cowen, Piper Jaffray · In the order on the cover
- Shares delivered
- On or about Nov 20, 2017
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Aug 10, 2017 |
| Filed publicly | Oct 20, 2017 |
| Amended twice | Newest Nov 15, 2017 |
| Shares registered with an exchange | Nov 15, 2017 |
| Declared effective by the SEC | Nov 15, 2017 |
| Final prospectus, with the price | Nov 17, 2017 |
Filings
| Filing | Filed |
|---|---|
| 424B1 · Prospectus | Nov 17, 2017 |
| EFFECT · Notice that a registration is effective | Nov 15, 2017 |
| CERTNAS · Nasdaq's certificate of listing | Nov 15, 2017 |
| S-1/A · Registration statement, amended | Nov 15, 2017 |
| 8-A12B · Registration of shares for listing on an exchange | Nov 15, 2017 |
| CORRESP · Letter to the SEC | Nov 13, 2017 |
| CORRESP · Letter to the SEC | Nov 13, 2017 |
| S-1/A · Registration statement, amended | Nov 6, 2017 |
| CORRESP · Letter to the SEC | Oct 26, 2017 |
| CORRESP · Letter to the SEC | Oct 20, 2017 |
All 16 filings
| Filing | Filed |
|---|---|
| S-1 · Registration statement | Oct 20, 2017 |
| UPLOAD · Letter from the SEC | Oct 4, 2017 |
| DRSLTR · Letter to the SEC with a draft | Sep 20, 2017 |
| DRS/A · Draft registration statement, amended | Sep 20, 2017 |
| UPLOAD · Letter from the SEC | Sep 6, 2017 |
| DRS · Draft registration statement | Aug 10, 2017 |
Open IPO · From the cover of the final prospectus (424B1) filed Nov 17, 2017
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.50M | 2.60M | 0 | 0 | 0 | 3.00M | 0 | 0 | 0 | 0 |
| Cost of revenue | 5.76M | 797.0K | 0 | 0 | 1.89M | 1.23M | 672.0K | 103.0K | 195.0K | 300.0K |
| Gross profit | 28.9M | 1.76M | -2.00M | -1.99M | -1.89M | 3.00M | -672.0K | -103.0K | -195.0K | -300.0K |
| Research and development | 72.7M | 81.6M | 72.0M | 61.1M | 50.6M | 41.9M | 30.2M | 20.3M | 17.1M | 17.8M |
| Selling, general and administrative | 43.5M | 61.5M | 32.1M | 27.0M | 24.7M | 20.9M | 17.6M | 18.4M | 8.01M | 6.51M |
| Operating income | -86.9M | -36.4M | -107.5M | -87.6M | -85.1M | -59.9M | -51.7M | -29.1M | -22.2M | -24.3M |
| Depreciation and amortization | 1.28M | 796.0K | 419.0K | 513.0K | 499.0K | 351.0K | 103.0K | 103.0K | 71.0K | 285.0K |
| EBITDA | -85.6M | -35.6M | -107.1M | -87.1M | -84.6M | -59.5M | -51.6M | -29.0M | -22.2M | -24.1M |
| Interest expense | 8.88M | 8.77M | 5.78M | 3.99M | 3.64M | 2.69M | 2.15M | 720.0K | 490.0K | 2.52M |
| Income before tax | -79.2M | -37.1M | -101.1M | -93.8M | -88.7M | -62.0M | -52.8M | -33.3M | -22.0M | -23.0M |
| Income tax | 41.0K | 310.0K | 78.0K | 28.0K | 17.0K | 148.0K | 0 | 0 | 1.87M | 2.62M |
| Net income | -79.2M | -37.5M | -101.2M | -93.9M | -88.7M | -62.1M | -52.8M | -33.3M | -22.0M | -23.0M |
| Earnings per share, basic | -1.87 | -5.59 | -17.07 | -1.52 | -3.99 | -3.09 | -4.63 | -79.15 | -54.58 | -44.79 |
| Earnings per share, diluted | -1.87 | -5.59 | -17.07 | -1.52 | -3.99 | -3.09 | -4.63 | -79.15 | -54.58 | -44.79 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 217.0M | 55.7M | 99.2M | 121.7M | 81.8M | 78.7M | 126.2M | 8.13M | 26.7M | 15.2M |
| Short-term investments | 35.9M | 46.4M | 15.0M | 0 | ||||||
| Receivables | 573.0K | 1.07M | 0 | 1.15M | 747.0K | 917.0K | 0 | 2.86M | 1.61M | 1.34M |
| Inventory | 4.48M | 2.82M | 0 | -747.0K | 355.0K | 1.25M | ||||
| Current assets | 261.6M | 112.2M | 122.1M | 128.7M | 87.9M | 83.3M | 129.3M | 9.34M | 79.5M | 5.72M |
| Property, plant and equipment | 182.0K | 776.0K | 745.0K | 1.10M | 1.51M | 1.24M | 403.0K | 241.0K | 421.0K | 37.0K |
| Goodwill | 17.4M | 17.4M | 17.4M | 17.4M | 17.4M | 27.1M | 27.1M | 0 | ||
| Total assets | 290.5M | 146.4M | 147.3M | 155.6M | 117.2M | 122.9M | 160.7M | 9.94M | 81.3M | 7.60M |
| Accounts payable | 5.70M | 8.62M | 8.95M | 7.78M | 4.28M | 3.14M | 2.09M | 2.97M | 1.89M | 1.65M |
| Current liabilities | 25.8M | 32.9M | 22.9M | 22.3M | 14.0M | 11.9M | 9.45M | 7.91M | 10.7M | 12.1M |
| Long-term debt | 76.3M | 75.4M | 54.6M | 32.3M | 33.1M | 33.2M | 20.0M | 8.31M | 9.92M | 10.1M |
| Total debt | 75.0M | 75.0M | 55.0M | 32.5M | 32.5M | 32.5M | 20.0M | 10.0M | 12.2M | 15.3M |
| Total liabilities | 104.2M | 124.3M | 96.2M | 81.5M | 52.8M | 50.1M | 31.5M | 21.6M | 22.5M | 24.3M |
| Shareholders' equity | 186.3M | 22.1M | 51.1M | 74.1M | 64.4M | 72.8M | 129.2M | -77.1M | -44.5M | -23.1M |
| Shares outstanding | 90.9M | 5.70M | 167.4M | 121.7M | 28.1M | 16.3M | 16.1M | 351.7K | 14.3M | 16.1M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -85.6M | -130.9M | -96.5M | -77.1M | -70.9M | -58.8M | -48.1M | -25.4M | -21.3M | -21.6M |
| Capital spending | 0 | -326.0K | -60.0K | -103.0K | -615.0K | -1.36M | -174.0K | 0 | -378.0K | -73.0K |
| Free cash flow | -85.6M | -131.2M | -96.6M | -77.2M | -71.5M | -60.2M | -48.2M | -25.4M | -21.7M | -21.7M |
| Cash from investing | 8.15M | 67.0M | -14.9M | -103.0K | -615.0K | -1.36M | 27.2M | 0 | -378.0K | -73.0K |
| Cash from financing | 238.6M | 20.3M | 88.5M | 117.2M | 74.2M | 12.4M | 140.7M | 6.87M | 33.4M | 18.1M |
| Dividends paid | -12 | -13.9M | -12.4M | -20.0M | -45.7M | |||||
| Share buybacks | 0 | 0 | -2.00M | 0 | 0 | -1.13M | -197.0K | -87.0K | ||
| Change in cash | 161.4M | -43.8M | -22.8M | 39.9M | 2.41M | -47.4M | 119.6M | -18.6M | 11.7M | -3.67M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 13, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 4, 2026 | Quarterly report | SEC |
| 8-K · Current report | Oct 29, 2026 | Current report | SEC |
| 4 · Change in ownership | Oct 19, 2026 | Insider trade | SEC |
| 8-K · Current report | Oct 8, 2026 | Material contract | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 7, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 5, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 1, 2026 | Other filings | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G · Big-stake notice | Sep 21, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Sep 8, 2026 | Current report | SEC |
| 8-K · Current report | Sep 8, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 13, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 13, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 13, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 6, 2026 | Quarterly report | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 30, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 1, 2026 | Insider trade | SEC |
| 8-K · Current report | Jul 1, 2026 | Management or board change | SEC |
| EFFECT · Notice that a registration is effective | May 18, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 8-K/A · Current report, amended | May 13, 2026 | Management or board change | SEC |
| 4 · Change in ownership | May 13, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 12, 2026 | Other filings | SEC |
| 8-K · Current report | May 12, 2026 | Management or board change | SEC |
| CORRESP · Letter to the SEC | May 12, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 11, 2026 | Other filings | SEC |
| S-3 · Registration statement | May 6, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | May 6, 2026 | Quarterly report | SEC |
| ARS · Annual report to shareholders | Mar 20, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Mar 20, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Mar 20, 2026 | Meeting notice | SEC |
| S-8 · Registration statement for employee plans | Mar 17, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 17, 2026 | Annual report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 6, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 12, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 5, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 15, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 7, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 5, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 3, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 31, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 29, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 27, 2025 | Insider trade | SEC |
| 8-K · Current report | Oct 24, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Oct 24, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Oct 23, 2025 | Offer document | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 21, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 3, 2025 | Big-stake notice | SEC |
| 424B3 · Prospectus | Sep 18, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Sep 18, 2025 | Other filings | SEC |
| 8-K · Current report | Sep 17, 2025 | Management or board change | SEC |
| CORRESP · Letter to the SEC | Sep 15, 2025 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Sep 15, 2025 | Big-stake notice | SEC |
| UPLOAD · Letter from the SEC | Sep 15, 2025 | Other filings | SEC |
| S-3 · Registration statement | Sep 10, 2025 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Sep 10, 2025 | Offer document | SEC |
| D | Aug 25, 2025 | Other filings | SEC |
| 8-K · Current report | Aug 25, 2025 | Management or board change | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 20, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 19, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 18, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D · Big-stake notice | Aug 18, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Aug 15, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 14, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 14, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 14, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D · Big-stake notice | Aug 13, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Aug 13, 2025 | Material contract | SEC |
| 8-K · Current report | Aug 12, 2025 | Material contract | SEC |
| 10-Q · Quarterly report | Aug 8, 2025 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 18, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 3, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 23, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Jun 23, 2025 | Offer document | SEC |
| 8-K · Current report | Jun 11, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 3, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jun 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | May 1, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 1, 2025 | Results | SEC |
| DEF 14A · Proxy statement | Apr 25, 2025 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Apr 25, 2025 | Meeting notice | SEC |
| 8-K · Current report | Apr 24, 2025 | Current report | SEC |
| 8-K · Current report | Apr 18, 2025 | Meeting outcome | SEC |
| S-8 · Registration statement for employee plans | Mar 26, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 25, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 25, 2025 | Results | SEC |
| DEF 14A · Proxy statement | Mar 24, 2025 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Mar 14, 2025 | Meeting notice | SEC |
| 8-K · Current report | Mar 3, 2025 | Current report | SEC |
| 4 · Change in ownership | Feb 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 14, 2025 | Insider trade | SEC |
| 8-K · Current report | Feb 6, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 31, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 27, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 24, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 24, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 24, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 24, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 24, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 24, 2025 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Jan 16, 2025 | Offer document | SEC |
| 8-K · Current report | Jan 13, 2025 | Material contract | SEC |
| UPLOAD · Letter from the SEC | Jan 7, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 23, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Dec 13, 2024 | Other filings | SEC |
| 4 · Change in ownership | Nov 19, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 15, 2024 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2024 | Current report | SEC |
| 8-K · Current report | Nov 13, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 8, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 4, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Oct 22, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 16, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 15, 2024 | Other filings | SEC |
| 4 · Change in ownership | Oct 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 8, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 7, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 7, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 7, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 7, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 7, 2024 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Oct 4, 2024 | Offer document | SEC |
| 4 · Change in ownership | Sep 11, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 9, 2024 | Other filings | SEC |
| 8-K · Current report | Aug 16, 2024 | Current report | SEC |
| 8-K · Current report | Aug 9, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Aug 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 8, 2024 | Results | SEC |
| 8-K · Current report | Jul 19, 2024 | Current report | SEC |
| 8-K · Current report | Jun 27, 2024 | Current report | SEC |
| 8-K · Current report | Jun 11, 2024 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2024 | Insider trade | SEC |
| 8-K · Current report | May 22, 2024 | Current report | SEC |
| 8-K · Current report | May 9, 2024 | Acquisition or disposal | SEC |
| 10-Q · Quarterly report | May 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2024 | Results | SEC |
| ARS · Annual report to shareholders | Apr 29, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2024 | Meeting notice | SEC |
| 8-K · Current report | Apr 29, 2024 | Current report | SEC |
| 8-K · Current report | Apr 29, 2024 | Current report | SEC |
| 8-K · Current report | Apr 5, 2024 | Current report | SEC |
| 8-K · Current report | Apr 1, 2024 | Current report | SEC |
| 10-K · Annual report | Mar 21, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 21, 2024 | Results | SEC |
| 4 · Change in ownership | Mar 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 11, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 11, 2024 | Other filings | SEC |
This page holds 200 of 821 filings. Open Filings
Cap table
Built by 6ix from X4 Pharmaceuticals, Inc.’s releases · as of Nov 2, 2026
- Common shares
- 102,113,554
- Fully diluted
- 102,113,554
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 102,113,554 | Nov 2, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 2, 2026 | 102,113,554 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Carl Gordon Other companies: ADARx Pharmaceuticals, Inc. (Co-head Global Private Equity at OrbiMed Advisors · Since at least Sep 24, 2026); Electra Therapeutics, Inc. (Director · Since at least Sep 18, 2026); BlossomHill Therapeutics, Inc. (Board Member · Since at least Aug 6, 2026); Scribe Therapeutics Inc. (Director · Since at least Jul 23, 2026); Compass Therapeutics, Inc. (Founding Member, Managing Partner, and Co-Head of Global Private Equity, OrbiMed Advisors LLC · Since at least Jun 17, 2020); Keros Therapeutics, Inc. (Director · Since at least Apr 7, 2020); MBX Biosciences, Inc. (Director · Sep 12, 2024 – Feb 14, 2025 · Past); ArriVent BioPharma, Inc. (Director · Jan 25, 2024 – Jan 30, 2024 · Past); Theseus Pharmaceuticals Inc (Director · Oct 6, 2021 – Feb 14, 2024 · Past); Disc Medicine, Inc. (Director · Feb 5, 2021 – Oct 4, 2021 · Past); Terns Pharmaceuticals, Inc. (Director · Feb 4, 2021 – Jul 15, 2024 · Past); Kinnate Biopharma Inc (Director · Dec 2, 2020 – Apr 3, 2024 · Past); Adicet Bio, Inc. (Director · Sep 15, 2020 – Aug 21, 2024 · Past); ORIC Pharmaceuticals, Inc. (Director · Apr 23, 2020 – Jun 16, 2021 · Past); SpringWorks Therapeutics Inc (Director · Sep 12, 2019 – Sep 12, 2019 · Past); Prevail Therapeutics Inc (Director · Jun 19, 2019 – Jan 22, 2021 · Past); Turning Point Therapeutics Inc (Director · Apr 16, 2019 – Jun 15, 2020 · Past); Alector, Inc. (Director · Feb 6, 2019 – May 10, 2019 · Past); Armo Biosciences Inc. (Director · Jan 25, 2018 – Jun 22, 2018 · Past); Cartesian Therapeutics, Inc. (Director · Jun 21, 2016 – Jun 27, 2016 · Past); Intellia Therapeutics, Inc. (Director · May 5, 2016 – May 18, 2017 · Past); Acceleron Pharma Inc (Director · Sep 18, 2013 – Sep 18, 2013 · Past); Pacira BioSciences, Inc. (Director · Feb 2, 2011 – Feb 8, 2011 · Past); Amarin Corporation plc (Director · Dec 30, 2010 – Sep 4, 2012 · Past); BioCryst Pharmaceuticals, Inc. (Director · May 17, 2006 – May 17, 2006 · Past) | Director · Nov 15, 2017 – Jun 5, 2018 · Past |
| Michael Wyzga Other companies: Tvardi Therapeutics, Inc. (Board Member · Since at least Apr 15, 2025); Mereo BioPharma Group plc (Chairman of the Board · Since at least Jan 1, 2024); Kineta Inc. (See Remarks · Aug 16, 2021 – Dec 2, 2022 · Past); Invivyd, Inc. (Director · Aug 5, 2021 – May 23, 2023 · Past); LogicBio Therapeutics Inc (Director · Oct 18, 2018 – Nov 16, 2022 · Past); EXACT Sciences Corporation (Director · Feb 9, 2015 – Feb 26, 2021 · Past); Akebia Therapeutics, Inc. (Director · Mar 19, 2014 – Jun 14, 2018 · Past); OncoMed Pharmaceuticals Inc (Director · Oct 14, 2013 – Jun 22, 2018 · Past); Idenix Pharmaceuticals Inc (Director · Mar 1, 2012 – Aug 5, 2014 · Past); Radius Health, Inc. (Chief Executive Officer, Director · Dec 5, 2011 – Dec 15, 2011 · Past); Genzyme Corp (Executive VP and CFO · May 25, 2006 – Apr 4, 2011 · Past) | Director · Since at least Mar 13, 2019 |
| Terrance McGuire Other companies: Tectonic Therapeutic, Inc. (Director · Since at least Jun 20, 2024); Invivyd, Inc. (Director · Since at least Aug 5, 2021); Seer, Inc. (Director · Since at least Dec 3, 2020); Cyclerion Therapeutics, Inc. (Director · Apr 1, 2019 – Nov 30, 2023 · Past); Alector, Inc. (Director · Feb 6, 2019 – Sep 11, 2023 · Past); Pulmatrix, Inc. (Director · Jun 15, 2015 – May 16, 2019 · Past); Trevena, Inc. (Director · Jan 30, 2014 – May 14, 2014 · Past); Acceleron Pharma Inc (Director · Sep 18, 2013 – Mar 2, 2017 · Past); Ironwood Pharmaceuticals, Inc. (Director · Jun 3, 2013 – Apr 1, 2019 · Past) | Director · Nov 15, 2017 – Jun 5, 2018 · Past |
| Alison Frances Lawton Other companies: ProQR Therapeutics N.V. (Director · Since at least Mar 18, 2026); Dianthus Therapeutics, Inc. (Director · Since at least Dec 22, 2020); Spyre Therapeutics, Inc. (Director · Dec 15, 2020 – Jun 22, 2023 · Past); Kaleido Biosciences, Inc. (See Remarks, Director · Feb 27, 2019 – Apr 15, 2020 · Past); CoLucid Pharmaceuticals Inc (Director · Mar 11, 2016 – Mar 1, 2017 · Past); Tempest Therapeutics, Inc. (Chief Operating Officer · Jan 21, 2013 – Jun 7, 2013 · Past); Verastem, Inc. (Director · Nov 26, 2012 – Jun 21, 2019 · Past); Cubist Pharmaceuticals Inc (Director · Feb 15, 2012 – Jan 21, 2015 · Past) | Director · Oct 5, 2020 – Jun 10, 2024 · Past |
| Amy Schulman Other companies: Elevance Health, Inc. (Director · Since at least Dec 10, 2025); Fractyl Health, Inc. (Director · Since at least Feb 1, 2024); Alnylam Pharmaceuticals, Inc. (Director · Since at least Jun 20, 2018); Hudson Executive Investment Corp II (Director · Jan 25, 2021 – Apr 13, 2021 · Past); Cyclerion Therapeutics, Inc. (Director · Apr 1, 2019 – Jun 16, 2020 · Past); Ironwood Pharmaceuticals, Inc. (Director · May 31, 2018 – Apr 1, 2019 · Past); Blue Buffalo Pet Products Inc (Director · Apr 24, 2018 – Apr 24, 2018 · Past) | Director · Nov 15, 2017 – Jun 5, 2018 · Past |
| Isaac Blech Other companies: Aridis Pharmaceuticals Inc. (Director · Aug 13, 2018 – Aug 13, 2018 · Past); InspireMD Inc. (Director · Jan 22, 2016 – Dec 7, 2016 · Past); Avalo Therapeutics, Inc. (Director · Oct 14, 2015 – Dec 31, 2018 · Past); PDS Biotechnology Corporation (Director · Sep 30, 2015 – Mar 15, 2019 · Past); SpendSmart Networks Inc (Director · Aug 1, 2014 – Jul 19, 2016 · Past); CervoMed Inc. (Director · Jul 24, 2014 – Aug 31, 2016 · Past); Aevi Genomic Medicine LLC (Director · Nov 11, 2013 – Apr 15, 2016 · Past) | Director · Mar 13, 2019 – Mar 13, 2019 · Past |
| David McGirr Other companies: Rhythm Pharmaceuticals, Inc. (Director · Since at least Oct 4, 2017); Insmed Incorporated (Director · Since at least Oct 30, 2013); Roka Bioscience Inc (Director · Jul 16, 2014 – Jun 28, 2017 · Past); Relypsa Inc (Director · Nov 14, 2013 – Sep 1, 2016 · Past); Cubist Pharmaceuticals Inc (SVP & Chief Financial Officer · Mar 31, 2010 – Feb 15, 2013 · Past) | Director · Since at least Nov 15, 2017 |
| Michael Jay Ross Other companies: Xilio Therapeutics, Inc. (Director · Oct 21, 2021 – Jun 15, 2022 · Past); Sutro Biopharma, Inc. (Director · Sep 26, 2018 – Sep 27, 2018 · Past); Deciphera Pharmaceuticals LLC (Director · Sep 27, 2017 – Jun 11, 2019 · Past); Astria Therapeutics Inc (Director · Jun 24, 2015 – Jun 7, 2018 · Past); IVERIC bio Inc (Director · Sep 24, 2013 – May 23, 2018 · Past) | Director · Nov 15, 2017 – Jun 5, 2018 · Past |
| Keith Woods Other companies: Neurogene Inc. (Director · Since at least Jun 12, 2025); Scholar Rock Holding Corporation (Chief Operating Officer · Since at least Apr 27, 2025); TScan Therapeutics, Inc. (Director · Since at least Dec 6, 2023); Rocket Pharmaceuticals, Inc. (Director · Dec 7, 2023 – Jun 13, 2024 · Past) | Director · Since at least Oct 16, 2023 |
| Murray Stewart Other companies: CAMP4 Therapeutics Corporation (Director · Since at least Mar 17, 2025); Amarin Corporation plc (Director · Jan 9, 2023 – Jan 9, 2023 · Past); Rhythm Pharmaceuticals, Inc. (Chief Medical Officer · Oct 15, 2018 – Feb 11, 2021 · Past); Novelion Therapeutics Inc (Executive Vice President, R&D · Nov 27, 2017 – Feb 12, 2018 · Past) | Board Member · Since at least Mar 29, 2019 |
All 35 people
| Person | Seat |
|---|---|
| Gary L. Bridger Other companies: Xenon Pharmaceuticals Inc. (EVP, Research & Development · Nov 4, 2014 – Nov 21, 2014 · Past); Alder BioPharmaceuticals Inc (Director · May 7, 2014 – Oct 31, 2015 · Past); Neurogene Inc. (Director · Mar 6, 2014 – May 7, 2018 · Past) | Board Member · Since at least Mar 13, 2019 |
| Michael Gray Other companies: Upstream Bio, Inc. (CFO and COO · Since at least Oct 10, 2024); POINT Biopharma Global Inc (Director · Jul 7, 2020 – Jul 7, 2020 · Past); Enliven Therapeutics, Inc. (CFO & COO · Mar 11, 2020 – Feb 22, 2023 · Past) | President, CEO and CFO, Director · Nov 15, 2017 – Nov 27, 2018 · Past |
| William D Clark Other companies: Aldeyra Therapeutics, Inc. (Director · Since at least Apr 17, 2025); iBio, Inc. (Director · Since at least Aug 23, 2021); Vanda Pharmaceuticals Inc. (Sr. VP, Chief Business Officer · Apr 12, 2006 – Feb 19, 2010 · Past) | Director · Nov 15, 2017 – Jun 5, 2018 · Past |
| Adam Craig Other companies: CTi Biopharma Corp (President and CEO, Director · Mar 20, 2017 – Jun 26, 2023 · Past); Sunesis Pharmaceuticals Inc (EVP, Development & CMO · Feb 27, 2012 – Feb 27, 2015 · Past) | Executive Chair · Since at least Aug 12, 2025 |
| Christophe Arbet-Engels Other companies: Altimmune, Inc. (Chief Medical Officer · Since at least Oct 1, 2025); Tempest Therapeutics, Inc. (Chief Medical Officer · Feb 10, 2020 – May 25, 2020 · Past) | Chief Medical Officer · Aug 16, 2023 – Nov 4, 2026 · Past |
| Lynne E Kelley Other companies: Ocugen, Inc. (Chief Medical Officer · Jul 31, 2018 – Oct 1, 2018 · Past); Senseonics Holdings, Inc. (Chief Medical Officer · Mar 17, 2016 – Feb 2, 2018 · Past) | See Remarks · Apr 24, 2019 – Apr 24, 2019 · Past |
| René Russo Other companies: Xilio Therapeutics, Inc. (President and Chief Executive Officer · Since at least Oct 21, 2021); Invivyd, Inc. (Director · Aug 5, 2021 – Aug 5, 2021 · Past) | Director · Nov 15, 2017 – Jun 2, 2021 · Past |
| Tillman U Gerngross Other companies: Invivyd, Inc. (Chief Executive Officer, Director · Aug 5, 2021 – Jan 30, 2022 · Past); Alector, Inc. (Director · Feb 6, 2019 – Jun 14, 2023 · Past) | Director · Nov 15, 2017 – Jun 5, 2018 · Past |
| David Kirske Other companies: CTi Biopharma Corp (EVP, Chief Financial Officer · Aug 1, 2017 – Jun 26, 2023 · Past) | Chief Financial Officer · Since at least Aug 12, 2025 |
| Derek Meisner Other companies: Acumen Pharmaceuticals, Inc. (Chief Legal Officer & Corp Sec · Since at least Sep 6, 2022) | Chief Legal Officer · Nov 4, 2019 – Aug 17, 2022 · Past |
| Diego Cadavid Other companies: Fulcrum Therapeutics, Inc. (SVP Clinical Development · Jul 17, 2019 – Jul 1, 2020 · Past) | Chief Medical Officer · Dec 14, 2020 – Mar 1, 2022 · Past |
| Mark Baldry Other companies: Wave Life Sciences Ltd. (Chief Commerical Officer · Aug 5, 2019 – Aug 5, 2019 · Past) | Chief Commercial Officer · Nov 3, 2022 – May 16, 2025 · Past |
| Paula Ragan Other companies: CAMP4 Therapeutics Corporation (Director · Since at least Oct 10, 2024) | CEO & President · Since at least Mar 13, 2019 |
| William Aliski Other companies: Ultragenyx Pharmaceutical Inc. (Director · Jan 30, 2014 – Jun 24, 2021 · Past) | Director · Sep 18, 2019 – Jun 10, 2024 · Past |
| Adam Mostafa | Chief Financial Officer · Mar 13, 2019 – Nov 4, 2026 · Past |
| Anthony Chris Stevens | Chief Medical Officer · Nov 15, 2017 – Mar 7, 2018 · Past |
| Arthur Taveras | Chief Scientific Officer · Nov 2, 2020 – Oct 4, 2024 · Past |
| Claudio Nessi | Director · Nov 15, 2017 – Jun 5, 2018 · Past |
| David Mantus | Chief Development Officer · Nov 15, 2017 – Mar 7, 2018 · Past |
| Eszter Nagy | Chief Scientific Officer · Nov 15, 2017 – Mar 7, 2018 · Past |
| Françoise de Craecker | Board Member · Since at least Oct 14, 2021 |
| John Volpone | President, Chief Operating Officer · Since at least Aug 12, 2025 |
| Mary DiBiase | Chief Operating Officer · Sep 8, 2021 – Feb 12, 2025 · Past |
| Natasha Fay Thoren | Chief Legal Officer · May 20, 2025 – May 20, 2025 · Past |
| Renato Skerlj | Chief Scientific Officer · Jun 10, 2020 – Sep 9, 2020 · Past |
Log in to ask 6ix AI your own questions about X4 Pharmaceuticals, Inc.